Rett and a brief then to update Suku you, will update recent then Thank provide syndrome. continued for activities, for conference remarks third with our call. Kamran I financial follow provide the our R&D will and closing clinical for begin drive on and and everyone, program open an adult and lead to third clinical and and TSHA-XXX TSHA-XXX up financial up results President the corporate on of our call and Nagendran, evaluation Hayleigh, Head with of welcome, our XXXX Taysha, quarter will across Alam, I Chief questions.
In will update syndrome. with adolescent update. program our quarter, Rett a Financial we pediatric, progress evaluation Officer, patients
clinical enrolling REVEAL trials, CMC different Phase high-dose support designation and additional regulatory completed recently across further the Medicine of accomplishments achieving families of cohort as was safety and the our disease, included multidisciplinary and in development Our B syndrome.
We suffering benefit from FDA TSHA-XXX of across expeditious our Rett additional both RMAT and for of adolescent/adult our that patients which and granted Regenerative with the supporting data I/II or for progress, Advanced Type a meeting important receiving Therapy, initial patients TSHA-XXX. TSHA-XXX clinical collecting ages profile pediatric stages our
We with for are the with set FDA discussions pathway potential trial Part B trials. for endpoints, natural as advance the design, our regulatory the and of elucidating data history pleased REVEAL use potential of made on established on the further we progress TSHA-XXX an
meeting, our activities Part to for we progress, with TSHA-XXX. plan use Suku CMC Type product a senior approval strong We the final process. our CMC by Additionally, we on derived this aligned FDA B was product, for use analytical are between more the FDA a cadence position based B we product in pivotal officials. comparability discuss of trials the Subsequently, REVEAL attended manufacturing TSHA-XXX.
We in will our the to to on the we demonstration in a commercial a expedite this believe we released with TSHA-XXX With recently of which development obtained successful including well meeting the and from clinical in trials. detail. FDA, pivotal the completed product the which intend
total events TSHA-XXX share of X, both review for in dose Reveal an the the We following high the X enrollment pediatric the in trials, Subsequently, TSHA-XXX for cohort data the patient high also trial treated encouraging patient enrolled adult received Monitoring the the from the I/II proceed of pleased current from and with XX vector dosed or was safety with Committee, I XX toxicities dosing the the high Data genomes available Cohort dose approval no adult in X evaluating serious we Phase first well-tolerated the weeks patients of third treatment. to patient pediatric clinical of and scheduled at the X with TSHA-XXX of the weeks generally of profile. the adolescent and to IDMC's the Independent in IDMC, demonstrate continued adverse weeks trial respectively, first as dose-limiting X continues quarter. to am post or adolescent cohort high-dose with of second high-dose the dose. treatment, post patients in X of
under- and care multisystem loss States, cause is expectancy. in patients estimated and development, the to with gene in mosaic it X-linked novel express address the and motor typically As for expression intellectual a of caused resulting significant We miRARE delivery the inactivation silencing afflicts regression and we Rett central patients are Individuals results a treat the United burden syndrome By to in expression molecules a require to function, minimally-invasive Rett has gene designed approaches a XX/X lifelong root in seizures, to both gene syndrome mixture reminder, disease, normally. slowing Rett daily dysfunction, has to neuronal confident characterized across of over-expression is transgene impact which challenging It's syndrome a that the and Rett in expressing intrathecally-delivered system unmet that appropriately TSHA-XXX, and disorder administered syndrome both the cell-by-cell due neurodevelopmental believe be life. potential pattern by Rett mediating is impairment, the controlled an XX,XXX MECPX. children leads with with broad benefit potential are that and the production United syndrome adults.
TSHA-XXX MECPX traditional significant to onetime, which provide MECPX and to of therapy XX,XXX and communication risks treat the disease-modifying there is miRARE equipped Kingdom. is cells of either central and shortened enabling small that by with strategically the protein caregiver is nervous or on or inhibits basis. differentiated random a to in with that disabilities, activities, development MECPX a respiratory need. the technology, cells, remain complications. and in hand system. of Currently, to MECPX subsequent enable there healthy transgene expression setting and of and assistance has potential on approach in of this population gene, with therapy of nervous optimal life associated mutations the high overcome in was the We autonomic to to genetic the quality Europe, MECPX outpatient cells and designed our rare therapies approved candidate, deficient in deficient therapeutic using therapy no challenge believe by meaningful and
have effectiveness which is the able gene, benefit domains a Importantly, for transduction. genome that were therapeutic miniMECPX contains double-stranded the We our vectors smaller decision packaging MECPX to of of that functional because bypass we but gene, converting our with than capsid of to gene more package important essential construct faster into they enhance a the version transduction paired utilize vector. self-complementary made DNA the the gene is efficient to a viral to the prior the able Self-complementary expression. necessary smaller traditional and so capacity vectors, a a the single-stranded of advantage to with entirely self-complementary genome the step vector offer they're
the dose of strategic consistent potentially seen enable improvements the over can of Rett strengthened of we've clinical believe the impact speed is of early can in and gene be response time their protein of requires regaining enable as disease. and skills treatment, an the transgene clinical by for therapy.
We protein new also patients reversing the that necessary efficacy for the of activities outcomes. that pediatric and outcomes. of TSHA-XXX. with learning low skills benefit create attributes persisted is the strengthen clinical strengthen strong observed adult potential clinical Therefore, MECPX a increases that the may Since likelihood We longer-term disease clinical early positive and neural therapeutic the circuits affected turn, levels patients indicator reactivated in self-complementary up the gain patients to MECPX result, opportunity living. a and positively daily and improvement believe the a these Rett these As sooner greater onset reached early progressive trajectory in to expression believe syndrome that, improve deeper increased a further time our the function, of activate it the the is trajectory vector of for to impact circuits we to the syndrome construct has disease, treated following requires predictive long-term and
Importantly, from time. pattern a with of the clinical adult clinical data domains with of multiple dose treatment gains post stage presented most the of indicate advanced functional within that the the across weeks and low persisted disease TSHA-XXX and treated early over improvements patients X the strengthened
petting function, impacting gross seizure demonstrated and and multiple investigator. daddy, and observations by device fine This X daily use iDates-driven measures reported to autonomic or including and use by communication, attentiveness, post efficacy utensils, members and and communication interactions without improved domains functional family as as clinical early in dog, weeks events. improvements principal Specifically, weeks, includes support, reported skills, X as the including eating gains and treatment. were sleep were beginning socialization improvements evidence, video improved activities, a mama social of At clinical documented motor sitting with breathing across and/or saying
evaluating the we forward the over look strength anticipate treated neural functional should pediatric strengthen over with also patients to observed early to matures network skills. gain data improvements TSHA-XXX develop in pediatric complex the the persist further patients clinical patients We pediatric As mature, and gains and and as time. the the that more time
treat leverages administration pathology, skills, distribution has are to to enables important has it intrathecal as the We throughout note that including we diseases, genetic CNS events. effective the Preclinical through the biodistribution disease improvements of approach the showed widespread believe cord. important of a and clinical our across method and findings to motor the progresses, support clinical reported seizure spinal the and outpatient communication autonomic demonstrated delivery gross setting. and data for consistent potential program that -- data across this of gene administered TSHA-XXX designed brain key widespread evaluation domains and delivery root in cause that therapies that fine in further been is routine clinical broad an clinical as As be AAV-based the clinical minimally-invasive it potential socialization,
and saw which we analysis in ESGCT studies pediatric over of of to Congress in-depth RMAT the on recently in consistently the reaches clinical both now of of areas TSHA-XXX what early, to the Suku dose disease intrathecal to the focused date and impactful year we REVEAL in construct was from the as we gene of X data REVEAL the expect longer-term differences mechanism pathway plan see is improvements key treated with for the multiple Importantly, and Annual FDA reinforced believe and remain and gains will and Suku brain safety reported provide turn demonstrated more and functional totality cord. discuss trials, believe working of improvements look we we encouraging with reporting delivery and have despite efficacy has based cohort spinal we to low X adult of cohort for a the presented strengthen ahead.
I an TSHA-XXX across depth.
Collectively, execution patients severity. to the closely that Suku? and this at X first over the design as therapies prepare through more XXXX. potential we low-dose We the in contributed this that regulatory to the ] time strategic will high-dose solidify the that new in be mature, forward the data we data sustained translationally with our data primate there to nonhuman from We call half to in baseline This discussion trials both the [ TSHA-XXX. of from the on continued to the data continue domains. data, demonstrating
